Prediction of drug terminal half-life and terminal volume of distribution after intravenous dosing based on drug clearance, steady-state volume of distribution, and physiological parameters of the body

Journal of Pharmaceutical Sciences

Volumn 102, Issue 2, 2013, Pages 761-771

  Berezhkovskiy, Leonid M ^a  

^a GENENTECH INC   (United States)

Author keywords

Blood flow; Blood plasma ratio; Clearance; Elimination; Physiological model; Prediction of human pharmacokinetics; Residence time; Steady state volume of distribution; Terminal half life and volume of distribution

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; DESIPRAMINE; DEXAMETHASONE; DIAZEPAM; DICLOFENAC; DILTIAZEM; DIPHENHYDRAMINE; HEXOBARBITAL; IMIPRAMINE; KETAMINE; LORCAINIDE; METHOXSALEN; MIDAZOLAM; PREDNISONE; QUINIDINE; SILDENAFIL; TENIDAP; TENOXICAM; TOLBUTAMIDE; VERAPAMIL; WARFARIN; ZOLPIDEM;

ACCURACY; ALLOMETRY; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BIOLOGICAL MODEL; BLOOD LEVEL; BLOOD VOLUME; BOLUS INJECTION; CALCULATION; COMPUTER MODEL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STABILITY; EXPERIMENTAL DOG; EXPERIMENTAL MONKEY; HEART OUTPUT; HUMAN; INTRAVENOUS ADMINISTRATION; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; RAT; STEADY STATE; TISSUE LEVEL;

EID: 84872498098     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23396     Document Type: Article

References (48)

1. Weiss M, Forster W. 1979. Pharmacokinetic model based on circulatory transport. Eur J Clin Pharmacol 16:287-293.
2. Berezhkovskiy LM. 2004. Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination. J Pharm Sci 93:1628-1640.
3. Rodgers T, Rowland M. 2006. Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 95:1238-1257.
4. Poulin P, Theil F-P. 2002. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J Pharm Sci 91:129-156.
5. ss. J Pharm Sci 96:1638-1652.
6. Berezhkovskiy LM. 2011. On the accuracy of estimation of basic pharmacokinetic parameters by the traditional non-compartmental equations and the prediction of the steady state volume of distribution in obese patients based upon data derived from normal subjects. J Pharm Sci 100:2482-2497.
7. Berezhkovskiy LM. 2011. On the influence of hepatic transport on the distribution volumes and mean residence time of drug in the body and on the accuracy of estimating these parameters by the traditional pharmacokinetic calculations. J Pharm Sci 100:5031-5047.
8. Mordenti J. 1985. Pharmacokinetic scale-up: Accurate prediction of human pharmacokinetic profiles from animal data. J Pharm Sci 10:1097-1099.
9. Rodgers T, Rowland M. 2007. Mechanistic approaches to volume of distribution predictions: Understanding the processes. Pharm Res 245:918-933.
10. Turner D, Ed. 2008. Simcyp population-based ADME simulator user manual, version 8. Sheffield, UK: Simcyp Limited, Blades Enterprise Centre, 232 pages including appendices and references.
11. Berezhkovskiy LM. 2012. Conceptual underestimation of the total body clearance by the sum of clearances of individual organs in physiologically based pharmacokinetics. J Pharm Sci 101:4660-4665.
12. Korn GA, Korn TM. 1961. Mathematical handbook for scientists and engineers, New York: McGraw- Hill, Inc.
13. Kwon Y. 2000. Handbook of essential pharmacokinetics, pharmacodynamics and drug metabolism for industrial scientists. New York: Kluwer Academic/Plenum Publishers.
14. Hinderling PH. 1997. Red blood cells: A neglected compartment in pharmacokinetics and pharmacodynamics. Pharmacol Rev 49:279-295.
15. Berezhkovskiy LM, Zhang X, Cheong J. 2011. A convenient method to measure blood-plasma concentration ratio using routine plasma collection in in vivo pharmacokinetic studies. J Pharm Sci 100:5293-5298.
16. Obach RS. 1999. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350-1359.
17. Shibata Y, Takahashi H, Chiba M, Ishii Y. 2002. Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: An application of serum incubation method. Drug Metab Dispos 30:892-896.
18. Berezhkovskiy LM. 2011. The corrected traditional equations for calculation of hepatic clearance that account for the difference in drug ionization in extracellular and intracellular tissue water and the corresponding corrected PBPK equation. J Pharm Sci 100:1167-1183.
19. Niazi S. 1976. Volume of distribution as a function of time. J Pharm Sci 65:452-454.
20. Schulz P, Turner-Tamiyasu K, Smith G, Giacomini KM, Blaschke TF. 1983. Amitriptyline disposition in young and elderly normal men. Clin Pharmacol Ther 33:360-366.
21. Eichelbaum M, Mikus G, Vogelsang D. 1984. Pharmacokinetics of (1)-, (2)-, and (6)-verapamil after intravenous administration. Br J Clin Pharmacol 17:453-458.
22. Blyden GT, Greenblatt DJ, Scavone JM, Shader RI. 1986. Pharmacokinetics of diphenhydramine and a demethylated metabolite following intravenous and oral administration. J Clin Pharmacol 26:529-533.
23. Abernethyl DR, Divoll M, Greenblatt DJ, Harmatz JS, Shader RI. 1984. Absolute bioavailability of imipramine: Influence of food. Psychopharmacology (Berl) 83:104-106.
24. Klotz U, Muller-Seydlitz P, Heimburg P. 1978. Pharmacokinetics of lorcainide in man: A new antiarrythmic agent. Clin Pharmacokinet 3:407-418.
25. Brosen K, Gram LF. 1988. First-pass metabolism of imipramine and desipramine: Impact of the sparteine oxidation phenotype. Clin Pharmacol Ther 43:400-406.
26. Grant IS, Nimmo WS, McNicol LR, Clements JA. 1983. Ketamine disposition in children and adults. Br J Anaesth 55:1107-1111.
27. Greenblatt DJ, Pfeifer HJ, Ochs HR, Franke K, MacLaughlin DS, Smith TW, Koch-Weser J. 1977. Pharmacokinetics of quinidine in humans after intravenous, intramuscular and oral administration. J Pharmacol Exp Ther 202:365-378.
28. Walker DK. 1999. Pharmacokinetics and metabolism of sildenafil in mouse, rabbit, dog and man. Xenobiotica 29:297-310.
29. Muirhead GJ, Rance DJ, Walker DK, Wastall P. 2002. Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil citrate. Br J Clin Pharmacol 53(S1): 13S-20S.
30. Smith MS, Verghese CP, Shand DG, Pritchett EL. 1983. Pharmacokinetic and pharmacodynamic effects of diltiazem. Am J Cardiol 51:1369-1374.
31. Tsuei SE, Moore RG, Ashley JJ, McBride WG. 1979. Disposition of synthetic glucocorticoids. I. Pharmacokinetics of dexamethasone in healthy adults. J Pharmacokinet Biopharm 7:249-264.
32. Pickup ME. 1979. Clinical Pharmacokinetics of prednisone and prednisolone, Clin Pharmacokinet 4:111-128.
33. Mandelli M, Tognoni G, Garattini S. 1978. Clinical pharmacokinetics of diazepam. Clin Pharmacokinet 3:72-91.
34. Maguire KP, Burrows GD, Norman TR, Scoggins BA. 1980. Blood/plasma distribution ratios of psychotropic drugs. Clin Chem 26:1624-1625.
35. Heizmann P, Eckert M, Ziegler WH. 1983. Pharmacokinetics and bioavailability of midamidazolam. Br J Clin Pharmacol 16(Suppl 1):43S-49S.
36. Billard V, Gambus PL, Barr J, Minto CF, Corash L, Tessman JW, Stickney JL, Shafer SL. 1995. The pharmacokinetics of 8-methoxypsoralen following i.v. administration in humans. Br J Clin Pharmacol. 40:347-360.
37. Smith RB, Kroboth PD, Vanderlugt JT, Phillips JP, Juhl RP. 1984. Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration. Psychopharmacology (Berl) 84:452-456.
38. Durand A, Thénot JP, Bianchetti G, Morselli PL. 1992. Comparative pharmacokinetic profile of two imidazopyridine drugs: Zolpidem and alpidem. Drug Metab Rev 24:239-666.
39. Willis JV, Kendall MJ, Flinn RM, Thornhill DP, Welling PG. 1979. The pharmacokinetics of diclofenac sodium following intravenous and oral administration. Eur J Clin Pharmacol 16:405-410.
40. Martin W, Koselowske G, Töberich H, Kerkmann T, Mangold B, Augustin J. 1990. Pharmacokinetics and absolute bioavailability of ibuprofen after oral administration of ibuprofen lysine in man. Biopharm Drug Dispos 11:265-278.
41. Williams RL, Blaschke TF, Meffin PJ, Melmon KL, Rowland M. 1977. Influence of acute viral hepatitis on disposition and plasma binding of tolbutamide. Clin Pharmacol Ther 21:301-309.
42. Miners JO, Foenander T, Wanwimolruk S, Gallus AS, Birkett DJ. 1982. The effect of sulphinpyrazone on oxidative drug metabolism in man: Inhibition of tolbutamide elimination. Eur J Clin Pharmacol 22:321-326.
43. McAleer SD, Foondun AS, Feely M, Chrystyn H. 1997. Steady-state clearance rates of warfarin and its enantiomers in therapeutically dosed patients. Chirality 9:13-16.
44. Lane S, Al-Zubiedi S, Hatch E, Matthews I, Jorgensen AL, Deloukas P, Daly AK, Park BK, Aarons L, Ogungbenro K, Kamali F, Hughes D, Pirmohamed M. 2012. The population pharmacokinetics of R- and S-warfarin: Effect of genetic and clinical factors. Br J Clin Pharmacol 73:66-76.
45. King SY, Joslin MA, Raudibaugh K, Pieniaszek HJ Jr, Benedek IH. 1995. Dose-dependent pharmacokinetics of warfarin in healthy volunteers. Pharm Res 12:1874-1877.
46. Gardner MJ, Wilner KD, Hansen RA, Fouda HG, McMahon GF. 1995. Single and multiple dose pharmacokinetics of tenidap sodium in healthy subjects. Br J Clin Pharmacol 39 (S1):11S-15S.
47. Heintz RC, Guentert TW, Enrico JF, Dubach UC, Brandt R, Jeunet FS. 1984. Pharmacokinetics of tenoxicam in healthy human volunteers. Eur J Rheumatol Inflamm 7:33-44.
48. Breimer DD, Honhoff C, Zilly W, Richter E, van Rossum JM. 1975. Pharmocokinetics of hexobarbital in man after intravenous infusion. J Pharmacokinet Biopharm 3:1-11.